Baghdad (IraqiNews.com) — The State Company for Drug Industries and Medical Appliances in Samarra (SDI), an affiliate of the Iraqi Ministry of Industry and Minerals, announced on Monday, August 24, 2026, the successful domestic production of Moxifloxacin, a broad-spectrum fluoroquinolone antibiotic targeting five distinct bacterial infections, marking its first addition to the company’s manufacturing portfolio.

In an official statement received by IraqiNews.com, SDI Director General, Chemist Mohammed Abdul Qader Al-Nuaimi, confirmed that the formulation marks a key step in expanding state pharmaceutical production lines and bolstering domestic medical security.

Clinical Scope & Key Indications

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibiotic designed to treat severe and complex bacterial infections in adult patients, including:

Community-Acquired Pneumonia: Lower respiratory tract bacterial infections.

Acute Exacerbations of Chronic Bronchitis: Bacterial flair-ups affecting chronic obstructive airway passages.

Acute Bacterial Sinusitis: Severe sinus and nasal inflammation.

Skin and Soft Tissue Infections: Complicated and uncomplicated bacterial dermatological and subcutaneous infections.

Other Complex Bacterial Invasions: Broad-spectrum systemic coverage against susceptible Gram-positive and Gram-negative pathogens.

Strategic Importance for National Drug Security

Import Substitution: Domestic manufacturing directly reduces the Ministry of Health’s reliance on foreign imported antibiotics, conserving foreign exchange reserves.

National Pharmaceutical Localization: Aligns with Iraq’s industrial localization roadmap aimed at strengthening the domestic supply chain for critical medications.

Supply Chain Reliability: Ensures stable, high-quality, and cost-effective medical supplies for state healthcare facilities and the local private retail market.

The launch of Moxifloxacin comes as part of the Samarra facility’s broader modernization drive to introduce advanced active pharmaceutical ingredients (APIs) and expand local formulation capacities.

By localizing the manufacture of advanced broad-spectrum antibiotics, SDI continues to scale production lines to meet the clinical procurement requirements of Iraqi hospitals and healthcare centers.